Anthropic quietly builds a biological laboratory! Claude directs robots to conduct experiments, marking another step forward in AI-driven pharmaceutical development.

Anthropic is extending its artificial intelligence ambitions further into the field of real-world biology. This ChatGPT competitor has established a physical biological laboratory in the San Francisco Bay Area and is recruiting biochemistry professionals, indicating that its life science strategy is moving from computer simulations to real-world experiments.

On September 18, Reuters reported that two sources familiar with the matter revealed that Anthropic has begun building a physical laboratory and is actively recruiting talent in the field of biochemistry. Eric Kauderer-Abrams, the company's head of life sciences, confirmed the existence of the laboratory, stating, "The ultimate test of biology remains and will continue to be real laboratory work."

This move comes at a highly sensitive time for Anthropic. In the past two weeks, company researchers have warned that AI could lead to human extinction, and Anthropic has also disclosed instances where its systems have been used in biological weapons development. At the same time, the company is preparing for a potential $2 trillion IPO, and life sciences have become one of its most strategically important areas of investment in personnel and resources. Kauderer-Abrams stated that this is the company's "greatest opportunity yet" to achieve its mission.

From computational simulation to real-world experimentation

Establishing a physical biological laboratory, or "wet lab," signifies that Anthropic is beginning to validate the biological predictions and screening results generated by AI in computers through real-world experiments. Kauderer-Abrams stated that the company will adopt a model similar to biotechnology companies, with some experiments conducted in its own facilities and others carried out in collaboration with external partners.

Anthropic stated that the lab is not specifically for drug development, but did not provide further details. Recent job postings include a head of procurement and operations, as well as a protein and nucleic acid characterization expert; one job posting stated the goal of "accelerating progress in life sciences by an order of magnitude."

Kauderer-Abrams stated that the purpose of building the laboratory was to increase the speed of research and development, saying, "There are some things that can be done much faster in our own hands," and that he hopes to be able to "operate on the largest possible scale" in the future.

Acquisitions and collaborations expand the life sciences footprint

Anthropic also supplements its capabilities through acquisitions, software products, and collaborations with pharmaceutical companies. The company reportedly acquired startup Coefficient Bio for approximately $400 million in stock, using it as a key asset in building drug discovery tools.

The company also launched Claude Science and announced in June that it would independently operate drug programs, focusing on preclinical research that traditional pharmaceutical companies invest in due to insufficient potential returns. Meanwhile, Anthropic has provided AI services and tools to pharmaceutical companies such as Roche's Genentech, Bristol-Myers Squibb, and Novo Nordisk.

Launched in August, the Model Hardware Standard aims to enable AI systems to directly control experimental equipment, driving automation of experimental processes. Novartis CEO Vas Narasimhan joining Anthropic's board of directors further strengthens the company's ties with the pharmaceutical industry.

Regarding research and development direction, Kauderer-Abrams stated that AI has the potential to drive progress in disease areas previously considered "untreatable," such as the development of complex molecules like bispecific and trispecific antibodies. However, Anthropic currently does not participate in clinical trials, but instead focuses on areas underserved by the industry, such as preclinical research. Kauderer-Abrams emphasized that the company "is not competing with pharmaceutical and biotechnology companies that bring drugs to market."

Data and security challenges under expansion

As Anthropic delves deeper into biopharmaceutical research and development, customer data and potential competition have become issues of concern. The report, citing two sources familiar with the matter, suggests that pharmaceutical clients may worry that Anthropic could profit from their drug development data, even though the company promises to keep customer data segregated.

Kauderer-Abrams acknowledged this concern, stating that it was one of the reasons Anthropic was not participating in clinical trials and was instead focusing on untapped areas within the industry. However, as the company's own R&D capabilities improve, the boundary between customer data and its own research and development will continue to be a focus of attention.

Security issues are also more sensitive. Anthropic researchers recently warned of potential extreme biosafety risks posed by AI, and the company has also disclosed cases of its systems being used in biological weapons development. Against this backdrop, Anthropic's expansion of its physical R&D capabilities means it needs to further address AI security and data isolation issues while improving R&D efficiency.

For CEO Dario Amodei, entering the biopharmaceutical field was also driven by personal experience. He mentioned that his father passed away from an illness, and a cure didn't appear until years later. Anthropic hopes to use AI to shorten the R&D cycle, but from candidate molecules to drug launch, there is still a long process of safety and efficacy validation, and many candidate drugs ultimately fail to pass clinical trials.

Risk warning and disclaimerInvesting involves risk; please exercise caution. This article does not constitute personal investment advice and does not take into account the specific investment objectives, financial situation, or needs of individual users. Users should consider whether any opinions, views, or conclusions in this article are suitable for their specific circumstances. Any investment decisions made based on this information are at your own risk.